Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Yamo Pharmaceuticals Reports Positive Data from Phase 2 Study of L1-79 in Autism
Details : L1-79 is a tyrosine hydroxylase inhibitor expected to modulate the catecholaminergic pathways, and thereby improve the core autism spectrum disorder symptoms.
Brand Name : L1-79
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 30, 2024
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : L1-79 (DL-alpha-Methyltyrosine) is a tyrosine hydroxylase inhibitor which is under phase 2 clinical development . It is designed to improve the core socialization and communication symptoms of autism spectrum disorder (ASD).
Brand Name : L1-79
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 20, 2023
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Syros Pharmaceuticals
Deal Size : $130.0 million
Deal Type : Private Placement
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
Details : SM-88 (racemetyrosine) is an orally administered cancer metabolism-based therapy that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis.
Brand Name : SM-88
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 16, 2022
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Syros Pharmaceuticals
Deal Size : $130.0 million
Deal Type : Private Placement
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Syros Pharmaceuticals
Deal Size : $60.0 million
Deal Type : Merger
Details : In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME’s pipeline including SM-88 (D/L-alpha-metyrosine).
Brand Name : SM-88
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 05, 2022
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Syros Pharmaceuticals
Deal Size : $60.0 million
Deal Type : Merger
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results that SM-88 alone showed antiproliferative effects in each of the sensitive and resistant cells lines, and that the combination of SM-88 and MPS had an additive effect in these models.
Brand Name : SM-88
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 09, 2022
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer
Details : SM-88 (D/L-alpha-metyrosine), with MPS arm of Phase 2/3 platform trial in metastatic pancreatic cancer discontinued for futility on primary endpoint of overall survival.
Brand Name : SM-88
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 26, 2022
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : The Autism Impact Fund
Deal Size : Undisclosed
Deal Type : Financing
Details : As part of investment in Yamo to support a Phase 2 study of L1-79 in adolescents and adults with ASD. L1-79, the company’s lead candidate, is a tyrosine hydroxylase inhibitor designed to modulate the catecholaminergic pathways implicated in ASD.
Brand Name : L1-79
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 10, 2021
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : The Autism Impact Fund
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer
Details : SM-88 is an oral investigational modified proprietary tyrosine derivative that interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s na...
Brand Name : SM-88
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2021
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study demonstrated that SM-88 had promising efficacy and safety outcomes for prostate cancer patients while sparing testosterone. The study also demonstrated a reduction of CTCs that may prove to be a better surrogate for patient outcomes than PSA, p...
Brand Name : SM-88
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2020
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TYME Announces Outcome of Interim Futility Review for HopES Sarcoma Phase II Study
Details : The interim futility review of company's HopES Sarcoma Phase II clinical trial for SM-88 was completed in late July and, based on the analysis of the data and recommendations of Dr. Sant Chawla, the study will proceed with the current trial design as pla...
Brand Name : SM-88
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 11, 2020
Lead Product(s) : Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?